Norbert Bornfeld
Advanced in Retinal Detachment

Norbert Bornfeld

Essen, NW, DE 
Advanced in Retinal Detachment
Essen, NW, DE 
OverviewLocationsClinical Research

Overview

Norbert Bornfeld practices in Essen, Germany. Mr. Bornfeld is rated as an Advanced expert by MediFind in the treatment of Retinal Detachment. His top areas of expertise are Uveal Melanoma, Retinoblastoma, Melanoma of the Eye, Vitrectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 101 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Retinal Detachment.

Gender
Male

Locations

Essen, NW 45147, Germany
Other Locations
Duesseldorf, NW 40212, Germany
Duisburg, NW, Germany
Germany
Tuebingen, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA
A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA
Enrollment Status: Unknown
Publish Date: December 02, 2022
Intervention Type: Biological
Study Drug: Autologous Dendritic Cells Loaded with Autologous Tumor RNA
Study Phase: Phase 3

101 Total Publications

Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM).
Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM).
Journal: iScience
Published: May 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bornfeld's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile